All In Biotech

NDA 216403 · Travere

Filspari

Sparsentan · Oral · Endothelin Receptor Antagonist; Angiotensin 2 Receptor Blocker

NovelAccelerated approvalPriority reviewOrphan

CDER novel approval, Feb 17, 2023: To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Feb 17, 2023

Approved uses

4

Original approval plus efficacy supplements

Registered trials

10

2 Phase 3, 3 recruiting

FAERS reports

6,767

1,116 serious, 37 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HEPATOTOXICITY and EMBRYO-FETAL TOXICITY Because of the risk of hepatotoxicity, FILSPARI is available only through a restricted program called the FILSPARI REMS. Under the FILSPARI REMS, prescribers, patients, and pharmacies must enroll in the program [see Warnings and Precautions ( 5.1 , 5.2 )] . Hepatotoxicity Some Endothelin Receptor Antagonists (ERAs) have caused elevations of aminotransferases, hepatotoxicity, and liver failure. In clinical studies, elevations in aminotransferases (ALT or AST) of at least 3-times the Upper Limit of Normal (ULN) have been observed in up to 3.5% of FILSPARI-treated patients, including cases confirmed with rechallenge. Measure transaminases and bilirubin before initiating treatment and then every 3 months during treatment. Interrupt treatment and closely monitor patients who develop aminotransferase elevations more than 3-times ULN [see...

What it is approved for

From the label in effect Apr 9, 2026.

FILSPARI is an endothelin and angiotensin II receptor antagonist indicated: • To slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression ( 1.1 , 12.1 , 14.1 ). • To reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome ( 1.2 , 12.1 , 14.2 ). 1.1 Immunoglobulin A Nephropathy FILSPARI is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression [see Clinical Pharmacology ( 12.1 ), Clinical Studies ( 14.1 )]. 1.2 Focal Segmental Glomerulosclerosis FILSPARI is indicated to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome [see Clinical Pharmacology ( 12.1 ), Clinical Studies ( 14.2 )].

Mechanism: Sparsentan is a single molecule with antagonism of the endothelin type A receptor (ET A R) and the angiotensin II type 1 receptor (AT 1 R). Sparsentan has high affinity for both the ET A R (Ki= 12.8 nM) and the AT 1 R (Ki=0.36 nM), and greater than 500-fold selectivity for these receptors over the endothelin type B and angiotensin II subtype 2 receptors. Endothelin 1 and angiotensin II are thought to be involved in the pathogenesis of IgAN and FSGS via the ET A R and AT 1 R, respectively.

Therapeutic areas: Cardiovascular and metabolic · Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • FILSPARI · SPARSENTAN 400MG · TABLET, ORAL · Prescription
  • FILSPARI · SPARSENTAN 200MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sparsentan" as an intervention, any sponsor and status, largest first.

All 10 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dizziness984
  • fatigue887
  • hypotension750
  • off label use456
  • nausea455
  • headache403
  • product use in unapproved indication390
  • product administration error369
  • peripheral swelling354
  • pruritus317
  • product dose omission issue278
  • blood pressure decreased268

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20203
20216
20222
2023632
20241,221
20252,395
20262,508

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Filspari (Sparsentan)

2024 spending

$24.3M

Beneficiaries

323

2,074 claims

Per beneficiary

$75,225

$372.23 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$4,777,836
2024$24,297,520

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 13 on PubMed

Sponsor: Travere

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.